TY - JOUR
T1 - Efficacy and safety of tacrolimus compared with ciclosporin-A in renal transplantation
T2 - 7-Year observational results
AU - Krämer, Bernhard K.
AU - Montagnino, Giuseppe
AU - Krüger, Bernd
AU - Margreiter, Raimund
AU - Olbricht, Christoph J.
AU - Marcen, Roberto
AU - Sester, Urban
AU - Kunzendorf, Ulrich
AU - Dietl, Karl Heinz
AU - Rigotti, Paolo
AU - Ronco, Claudio
AU - Hörsch, Silke
AU - Banas, Bernhard
AU - Mühlbacher, Ferdinand
AU - Arias, Manuel
PY - 2016/3/1
Y1 - 2016/3/1
N2 - The European Tacrolimus versus Ciclosporin-A Microemulsion (CsA-ME) Renal Transplantation Study demonstrated that tacrolimus decreased acute rejection rates at 6 months. Primary endpoints of this investigator-initiated, observational 7-year follow-up study were acute rejection rates, patient and graft survival rates, and a composite endpoint (BPAR, graft loss, and patient death). We analyzed data from the original intent-to-treat population (n = 557; 286 tacrolimus, 271 CsA-ME). A total of 237 tacrolimus and 208 CsA-ME patients provided data. At 7 years, Kaplan-Meier estimated rates of patients free from BPAR were 77.1% in the tacrolimus arm and 59.9% in the CsA-ME arm, graft survival rates amounted to 82.6% and 80.6%, and patient survival rates to 89.9% and 88.1%. Estimated combined endpoint-free survival rates were 60.2% in the tacrolimus arm and 47.0% in the CsA-ME arm (P =
AB - The European Tacrolimus versus Ciclosporin-A Microemulsion (CsA-ME) Renal Transplantation Study demonstrated that tacrolimus decreased acute rejection rates at 6 months. Primary endpoints of this investigator-initiated, observational 7-year follow-up study were acute rejection rates, patient and graft survival rates, and a composite endpoint (BPAR, graft loss, and patient death). We analyzed data from the original intent-to-treat population (n = 557; 286 tacrolimus, 271 CsA-ME). A total of 237 tacrolimus and 208 CsA-ME patients provided data. At 7 years, Kaplan-Meier estimated rates of patients free from BPAR were 77.1% in the tacrolimus arm and 59.9% in the CsA-ME arm, graft survival rates amounted to 82.6% and 80.6%, and patient survival rates to 89.9% and 88.1%. Estimated combined endpoint-free survival rates were 60.2% in the tacrolimus arm and 47.0% in the CsA-ME arm (P =
KW - acute rejection
KW - adverse events
KW - calcineurin inhibitor
KW - investigator-initiated study
KW - long-term follow-up
UR - http://www.scopus.com/inward/record.url?scp=84958623991&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958623991&partnerID=8YFLogxK
U2 - 10.1111/tri.12716
DO - 10.1111/tri.12716
M3 - Article
AN - SCOPUS:84958623991
SN - 0934-0874
VL - 29
SP - 307
EP - 314
JO - Transplant International
JF - Transplant International
IS - 3
ER -